Petit M
Groupe de Recherche sur la schizophrénie, Université de Rouen, Centre hospitalier du Rouvray, Sotteville-lès-Rouen.
Encephale. 1994 Dec;20 Spec No 4:667-74.
A review of the international literature concerned with controlled studies of antidepressants in schizophrenics shows that the therapeutic efficacy of these agents is primarily a function of the phase in the disorder during which they are administered. During the acute phases, administration of antidepressants, with or without neuroleptics, is to be avoided since it can aggravate florid symptomatology. In "depressed" schizophrenics in the post-psychotic phase, some studies have favored combination of an antidepressant with a neuroleptic, in particular for prevention of disorders of mood, as well as of suicidal behavior. Nevertheless, from the methodologic standpoint, they are still numerous problems in differentiation between depressive symptomatology and akinetic symptoms or deficit symptomatology. Finally, in terms of efficacy of antidepressants for negative or deficit symptomatology, there are some data suggesting efficacy of a combination of an antidepressant with the standard neuroleptic treatment. Nevertheless, confirmation of such efficacy would require comparison with the disinhibitory neuroleptics.
一项关于精神分裂症患者抗抑郁药对照研究的国际文献综述表明，这些药物的治疗效果主要取决于给药时疾病所处的阶段。在急性期，应避免使用抗抑郁药，无论是否联用抗精神病药，因为这可能会加重明显的症状。在精神病后阶段的“抑郁性”精神分裂症患者中，一些研究支持将抗抑郁药与抗精神病药联用，特别是用于预防情绪障碍以及自杀行为。然而，从方法学角度来看，在区分抑郁症状与运动不能症状或缺陷症状方面仍然存在许多问题。最后，就抗抑郁药对阴性或缺陷症状的疗效而言，有一些数据表明抗抑郁药与标准抗精神病药治疗联用具有疗效。然而，要证实这种疗效需要与解除抑制性抗精神病药进行比较。
